In this accredited activity, a panel of national and international experts discuss current standards of care in AML, focusing on the ongoing challenges of treating patients who are unfit for intensive chemotherapy. Through an in-depth discussion of the role of genetic testing in the development of targeted, individualized therapeutic regimens, the faculty panel tackles recommended approaches for some of the most complex AML subtypes, including IDH1, FLT3 and TP53. After viewing this engaging discussion, participants will have a greater understanding of applied strategies for diagnosing and treating patients with AML, including the assessment of performance status versus a “gut feeling”, clinical trials as a treatment option, and the role of VEN-AZA in patients who are older or medically unfit.